4D Molecular Therapeutics' investment thesis is centered on the clinical execution of its adeno-associated virus (AAV) gene therapy pipeline, with its financial trajectory heavily dependent on lumpy, non-recurring collaboration milestones, as evidenced by the ...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$1.04-2.0% vs -$1.02 | $4M+4.4% vs $4M |
Q2 2026 May 7, 2026 | -$1.01-4.1% vs -$0.97 | $3M+17.8% vs $3M |
Q2 2026 Mar 18, 2026 | $0.43+181.1% vs -$0.53 | $85M+215.2% vs $27M |
Q4 2025 Nov 10, 2025 | -$1.01+1.0% vs -$1.02 | $90,000-99.7% vs $31M |
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have issued a buy recommendation and one
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company's board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Benchmark FDMT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for 4D Molecular Therapeutics, Inc. (FDMT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.88 | $830.15M | -6.56 | — | -164.43% | -27.57% | — | |
| $1.04 | $352.67M | -4.52 | 8.83% | -1786.27% | — | — | |
| $350.88 | $10.34B | 51.30 | 33.94% | 54.82% | 19.34% | — | |
| $3.35 | $365.8M | -1.67 | — | — | -5.76% | — | |
| $45.28 | $3.14B | -13.09 | -40.64% | -1350.73% | -111.96% | — | |
| $2.92 | $448.11M | -1.62 | 25.39% | -157.32% | -196.63% | — |
4D Molecular Therapeutics, Inc. (FDMT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
4D Molecular Therapeutics, Inc. (FDMT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 20, 2026·SEC
Jun 29, 2026·SEC
Get notified when FDMT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
4D Molecular Therapeutics, Inc. (FDMT) stock FAQ — growth, dividends, profitability & financials explained
4D Molecular Therapeutics, Inc. (FDMT) reported $92.0M in revenue for fiscal year 2025. This represents a 1489% increase from $5.8M in 2017.
4D Molecular Therapeutics, Inc. (FDMT) reported a net loss of $179.2M for fiscal year 2025.
4D Molecular Therapeutics, Inc. (FDMT) has a return on equity (ROE) of -27.6%. Negative ROE indicates the company is unprofitable.
4D Molecular Therapeutics, Inc. (FDMT) had negative free cash flow of $156.7M in fiscal year 2025, likely due to heavy capital investments.
